The active ingredient in the currently marketed Namenda XR® is memantine hydrochloride. Namenda XR is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Allergan owns the exclusive U.S. commercialization rights, while Adamas retains exclusive commercialization rights outside of the U.S. Adamas is eligible to receive royalties from Allergan for U.S. sales of Namenda XR beginning in June 2018.

Namzaric is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

Eligible to receive royalties on net sales of Namenda XR® beginning in 2018.